Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 3/20 | 0.51 |
| ▸ | ROR1 | Q01973 | 1/20 | 0.49 |
| ▸ | LCK | P06239 | 3/20 | 0.47 |
| ▸ | KDR | P35968 | 3/20 | 0.47 |
| ▸ | TEK | Q02763 | 3/20 | 0.47 |
| ▸ | CSF1R | P07333 | 2/20 | 0.45 |
| ▸ | KIT | P10721 | 8/20 | 0.42 |
| ▸ | DDR1 | Q08345 | 5/20 | 0.42 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.42 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.41 |
| ▸ | NNMT | P40261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4067236 | 0.89 | ABL1 (0.52) | ABL1ROR1LCKKDRTEK | |
| SCHEMBL4063551 | 0.84 | ABL1 (0.51) | ABL1ROR1LCKKDRTEK | |
| SCHEMBL21678130 | 0.80 | LCK (0.46) | ABL1ROR1LCKKDRTEK | |
| SCHEMBL18247791 | 0.79 | ABL1 (0.50) | ABL1ROR1LCKKDRTEK | |
| SCHEMBL21678129 | 0.79 | LCK (0.49) | ABL1ROR1LCKKDRTEK | |
| SCHEMBL18257151 | 0.78 | ABL1 (0.68) | ABL1ROR1LCKKDRTEK | |
| SCHEMBL29483761 | 0.76 | KIT (0.45) | ABL1LCKKDRTEKKIT | |
| SCHEMBL18247795 | 0.76 | KIT (0.45) | ABL1LCKKDRTEKKIT | |
| SCHEMBL3465475 | 0.75 | NNMT (0.69) | PTK2NNMT | |
| SCHEMBL18247796 | 0.75 | ABL1 (0.45) | ABL1ROR1LCKKDRTEK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127372-A1 | NOVEL AMIDOHETEROARYL AROYL HYDRAZIDE ETHYNES | SUN PHARMA ADVANCED RESEARCH COMPANY LTD. (IN) | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127372-A1 | NOVEL AMIDOHETEROARYL AROYL HYDRAZIDE ETHYNES | ERBB2, ABL1, ERBB3 | ABL1 2/4885ROR1 486/4885LCK 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.